Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 9/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065453 | 1.00 | CYP11B1 (0.42) | CYP11B1CYP11B2FNTAFNTBITGB1 | |
| SCHEMBL5065572 | 0.87 | FNTA (0.43) | CYP11B1CYP11B2FNTAFNTBITGB1 | |
| SCHEMBL5065564 | 0.87 | FNTA (0.43) | CYP11B1CYP11B2FNTAFNTBITGB1 | |
| SCHEMBL5067755 | 0.85 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL5067756 | 0.81 | ITGB1 (0.49) | ITGB1ITGA4 | |
| SCHEMBL5065590 | 0.81 | ITGB1 (0.66) | ITGB1ITGA4 | |
| SCHEMBL5065587 | 0.81 | ITGB1 (0.66) | ITGB1ITGA4 | |
| SCHEMBL5067758 | 0.81 | ITGB1 (0.49) | ITGB1ITGA4 | |
| SCHEMBL5067750 | 0.81 | ITGB1 (0.37) | CYP11B1CYP11B2ITGB1ITGA4 | |
| SCHEMBL27679888 | 0.79 | FNTA (0.38) | FNTAFNTBITGB1ITGA4PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | ITGB4, ITGA4, ICAM1 | CYP11B1 2539/4885CYP11B2 3072/4885FNTA 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.